Healthcare, Pharma & Life Sciences

European Commission medical devices conference signals 2026 scrutiny of EU sector priorities

Image

SHERIDAN, WYOMING - March 23, 2026 - Medical-device manufacturers, regulatory teams and healthcare procurement planners in Europe face a sharper 2026 focus on policy direction, oversight and innovation priorities as the European Commission convenes a high-level conference to assess recent sector developments and discuss what comes next. The meeting is scheduled for 16 March 2026 in Brussels and brings together Commissioner for Health Olivér Várhelyi, representatives from EU regulatory authorities, the Council, the European Parliament and experts from EU stakeholders' associations. The stated purpose is to take stock of recent key developments in the medical-devices sector and provide a view of the future, making the conference a concentrated signal of where policy and industry dialogue are heading within the EU framework.

IHI contributing partner rules widen 2026 options for health organizations backing EU research projects

Image

SHERIDAN, WYOMING - March 23, 2026 - Health organizations planning 2026 research participation in Europe gain a new route to influence project design, allocate in-kind resources, and support proposals without taking on full private-member status in the Innovative Health Initiative. MedTech Europe points to an 11 February 2026 webinar hosted by the IHI Office, focused on the contributing partner category for organizations that are not affiliated with an IHI private industry member, as well as organizations affiliated with a private member that need to understand how contributing partners can support proposals. The session is positioned around practical participation questions rather than broad program promotion, including eligibility, application steps, contribution rules, and common mistakes.

Clinical scope

Image

SHERIDAN, WYOMING - March 23, 2026 - European hospitals evaluating 2026 imaging, intervention, and workforce plans now have a new validation pathway for AI-assisted neurovascular and oncology procedures as the SHERPA consortium starts seven clinical studies focused on workflow automation, precision support, and staff-pressure reduction in minimally invasive care. The four-year project has a total budget of EUR 21.5 million, is coordinated by Philips, and is co-funded by the EU Innovative Health Initiative and industry partners. Its work targets minimally invasive treatment workflows for brain aneurysms, liver tumors, and lung biopsy settings where specialized expertise is limited and procedure complexity is high.

MMA page excerpt offers no verifiable details from cited "Daily AI News" item

Image

SHERIDAN, WYOMING - March 13, 2026 - The source material tied to MMA Global's "Daily AI News | Deploying Claws | March 13 2026" does not include usable editorial content beyond website scripts, navigation labels, and a marketing tagline. Based on the supplied excerpt, MMA Global is the only identifiable organization, but no verifiable business action, product development, partnership, funding event, or policy move can be confirmed. For decision-makers, that means there is no substantiated operational or commercial update to assess from the cited page as provided. The absence of reportable facts is itself material in a B2B publishing context that depends on source-backed claims.

Roche reports Phase II obesity data for petrelintide with 10.7% weight reduction at 42 weeks

Image

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.

Eli Lilly Reports Phase 3b Win for Taltz and Zepbound Combination in Psoriasis Patients With Obesity

Image
Eli Lilly Reports Phase 3b Win for Taltz and Zepbound Combination in Psoriasis Patients With Obesity

SHERIDAN, WYOMING - March 13, 2026 - Eli Lilly and Company has reported positive topline results from the Phase 3b TOGETHER-PsO trial, showing that concomitant use of Taltz and Zepbound outperformed Taltz monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. At 36 weeks, the combination met the primary endpoint and all key secondary endpoints, linking deeper skin clearance with clinically meaningful weight reduction in a patient population with high disease burden. For clinicians, payers, and commercial stakeholders in immunology and obesity care, the readout is significant because it supports a more integrated treatment model for patients whose outcomes may be affected by both inflammatory disease and elevated body weight. It also extends Lilly's argument that obesity management may influence psoriasis outcomes in difficult-to-treat populations.

USOPC and Lilly Scale Athlete Recovery Support Through LA28 With a Longer-Term Care Model

Image
USOPC and Lilly Scale Athlete Recovery Support Through LA28 With a Longer-Term Care Model

SHERIDAN, WYOMING - March 13, 2026 - The United States Olympic & Paralympic Committee is extending the Team USA Athlete Recovery Program with support from Eli Lilly and Company, turning what began as a pilot into a longer-term recovery model tied to the next major Olympic and Paralympic cycles. The program will continue after the Olympic and Paralympic Winter Games Milano Cortina 2026 and through the LA28 Olympic and Paralympic Games, with a focus on athletes facing complex or extended rehabilitation needs. For sports organizations, governing bodies, and healthcare-adjacent partners, the significance lies less in sponsorship optics than in how recovery services are being structured as an operational layer of athlete support. The announcement points to a more formal approach to coordinated care, continuity, and access beyond the competition window itself.

Program expansion formalizes recovery as an ongoing support function

MedTech Europe presses for industry role as HERA launches MCM working groups

SHERIDAN, WYOMING - March 09, 2026 - MedTech Europe participated in the first in‑person meeting of the HERA Industrial Cooperation Forum on 6 February 2026, a session in which the European Commission presented HERA's annual workplan and launched two technical working groups. The association used the meeting to underline the operational importance of medical technologies in health responses and to press for practical industry involvement in preparedness exercises. MedTech Europe also flagged the potential burden from additional reporting requirements and said forthcoming work will focus on supply‑chain risks and on supporting development, manufacturing, availability and accessibility of medical countermeasures.

BioSpace hiring data points to cautious biopharma job market stabilization as 12 employers lead posting volume

Image
BioSpace hiring data points to cautious biopharma job market stabilization as 12 employers lead posting volume

SHERIDAN, WYOMING - March 04, 2026 - Hiring signals in biopharma remain mixed but usable for employers and candidates: overall job-posting activity is described as lower year over year, yet slightly higher month over month, and a late-2025 survey cited in the source suggests a meaningful share of companies expect open roles to rise in 2026. For the market, the key message is not "boom or bust," but that recruiting is still happening-especially at scale players that must protect execution capacity across late-stage development, manufacturing, commercial operations, and enabling functions. For job seekers, this translates into real pharma and biotech opportunity concentrated in employers that are still running active pipelines.

FDA escalates compounded GLP-1 enforcement with 30 telehealth warning letters and manufacturing concerns at GenoGenix

Image
FDA escalates compounded GLP-1 enforcement with 30 telehealth warning letters and manufacturing concerns at GenoGenix

SHERIDAN, WYOMING - March 04, 2026 - The U.S. Food and Drug Administration has issued 30 warning letters to telehealth companies over compounded GLP-1 products promoted on their websites, extending an enforcement campaign that previously targeted larger players in the channel. FDA officials allege some companies made false or misleading claims, implied compounded products are the same as approved medicines, or obscured product sourcing by branding drugs with their own names or trademarks. The agency also flagged manufacturing and quality concerns at one compounder, GenoGenix, including conditions that could create contamination risk and reports of multiple emergency room visits tied to a compounded product.